Harbor Capital Advisors, Inc. Moon Lake Immunotherapeutics Transaction History
Harbor Capital Advisors, Inc.
- $2.38 Billion
- Q2 2025
A detailed history of Harbor Capital Advisors, Inc. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 51,409 shares of MLTX stock, worth $2.85 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
51,409
Previous 102,020
49.61%
Holding current value
$2.85 Million
Previous $3.99 Million
39.11%
% of portfolio
0.1%
Previous 0.18%
Shares
6 transactions
Others Institutions Holding MLTX
# of Institutions
160Shares Held
55.1MCall Options Held
451KPut Options Held
199K-
Bvf Inc San Francisco, CA19.8MShares$1.09 Billion33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$470 Million35.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.97MShares$165 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$153 Million1.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$81.9 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.04B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...